Next Article in Journal
Phytoplasma Infection Blocks Starch Breakdown and Triggers Chloroplast Degradation, Leading to Premature Leaf Senescence, Sucrose Reallocation, and Spatiotemporal Redistribution of Phytohormones
Previous Article in Journal
Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword
Previous Article in Special Issue
CLDN6 Suppresses c–MYC–Mediated Aerobic Glycolysis to Inhibit Proliferation by TAZ in Breast Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment

by
Carla M. Felcher
1,†,
Emilia S. Bogni
1,† and
Edith C. Kordon
1,2,*
1
Instituto de Fisiología, Biología Molecular y Neurociencias (IFIBYNE), Universidad de Buenos Aires—Consejo Nacional de Investigaciones Científicas y Técnicas (IFIBYNE-UBA-CONICET), Ciudad Autónoma de Buenos Aires (CABA) 1428, Argentina
2
Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires (CABA) 1428, Argentina
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2022, 23(3), 1809; https://doi.org/10.3390/ijms23031809
Submission received: 3 January 2022 / Revised: 19 January 2022 / Accepted: 20 January 2022 / Published: 5 February 2022
(This article belongs to the Special Issue The Promise of Precision Oncology in Breast Cancer)

Abstract

The IL-6 cytokine family is a group of signaling molecules with wide expression and function across vertebrates. Each member of the family signals by binding to its specific receptor and at least one molecule of gp130, which is the common transmembrane receptor subunit for the whole group. Signal transduction upon stimulation of the receptor complex results in the activation of multiple downstream cascades, among which, in mammary cells, the JAK-STAT3 pathway plays a central role. In this review, we summarize the role of the IL-6 cytokine family—specifically IL-6 itself, LIF, OSM, and IL-11—as relevant players during breast cancer progression. We have compiled evidence indicating that this group of soluble factors may be used for early and more precise breast cancer diagnosis and to design targeted therapy to treat or even prevent metastasis development, particularly to the bone. Expression profiles and possible therapeutic use of their specific receptors in the different breast cancer subtypes are also described. In addition, participation of these cytokines in pathologies of the breast linked to lactation and involution of the gland, as post-partum breast cancer and mastitis, is discussed.
Keywords: breast cancer; IL-6; LIF; OSM; IL-11; mastitis; tumor microenvironment breast cancer; IL-6; LIF; OSM; IL-11; mastitis; tumor microenvironment

Share and Cite

MDPI and ACS Style

Felcher, C.M.; Bogni, E.S.; Kordon, E.C. IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. Int. J. Mol. Sci. 2022, 23, 1809. https://doi.org/10.3390/ijms23031809

AMA Style

Felcher CM, Bogni ES, Kordon EC. IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. International Journal of Molecular Sciences. 2022; 23(3):1809. https://doi.org/10.3390/ijms23031809

Chicago/Turabian Style

Felcher, Carla M., Emilia S. Bogni, and Edith C. Kordon. 2022. "IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment" International Journal of Molecular Sciences 23, no. 3: 1809. https://doi.org/10.3390/ijms23031809

APA Style

Felcher, C. M., Bogni, E. S., & Kordon, E. C. (2022). IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment. International Journal of Molecular Sciences, 23(3), 1809. https://doi.org/10.3390/ijms23031809

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop